It is a reflection of the very significant potential of Evgen Pharma’s technology that the company has been able to attract a high calibre commercial, scientific and advisory team.
Barry Clare, Non-Executive Chairman
Barry has over 20 years’ experience in the healthcare industry. He was a main board director of the Boots Company plc and managing director of its successful consumer healthcare division, Boots Healthcare International, where he led the global expansion of a leading portfolio of brands including Nurofen, Strepsils and Clearasil. Since leaving Boots, he has set up his own company, Clarat Partners LLP, and engineered several private equity backed transactions. He is also the Non-Executive Chairman of University Hospital of South Manchester Foundation Trust.
Dr Stephen Franklin, Chief Executive Officer
Stephen, the founder of Evgen Pharma, has over 20 years’ commercial experience in life science industries, focusing on the commercialisation of new technology. He was the founder of Provexis plc, a nutraceutical company, and was its chief executive at the time of its admission to AIM in 2005. Prior to that, Stephen was a principal executive with ANGLE plc, the AIM quoted technology commercialisation company, having previously held a business development role with Manchester Biotech (now University of Manchester Innovation Company), one of the largest campus-based incubators in Europe; in these roles he helped establish a portfolio of drug discovery and development businesses. Stephen has a BSc in Biology (York), a PhD in Applied Biochemistry (Nottingham) and an MBA with distinction (Nottingham). He is a Fellow of the Royal Society of Medicine and an alumni of the Royal Commission for the Exhibition of 1851.
Richard Moulson, Chief Financial Officer
Richard is a qualified chartered accountant with over 20 years’ post-qualification experience working as a chief financial officer for UK quoted and private equity and venture capital owned companies. Richard trained with Coopers & Lybrand and spent 10 years with Deutsche Morgan Grenfell in corporate finance working on fundraisings, IPOs and M&A transactions in the UK and internationally. He has considerable life science experience in companies including Intercytex Group Plc, ReNeuron Group plc and Cobra Therapeutics Ltd, and currently provides part-time CFO and finance consulting services to SMEs with a focus on life science businesses.
Dr Alan Barge, Non-Executive Director
Alan is the former chief medical officer of Singapore-based ASLAN Pharmaceuticals PTE. Up until 2011, he was vice-president and head of oncology & infection at AstraZeneca, a role in which he was responsible for the overall strategy in oncology and infection from drug discovery to proof-of-concept. He was also chairman of AstraZeneca’s Therapy Area Portfolio Team and accountable for the design and delivery of all projects, including budgetary oversight. Prior to his career at AstraZeneca, Alan was European and global medical director for Amgen Inc.
Dr Susan Foden, Non-Executive Director
Susan has broad experience in executive and non-executive roles at both public and private companies and at funding organisations. Her current directorships include the chair of BerGenBio AS and non-executive roles at BTG plc and at Vectura Group plc. From 2000 to 2003, Susan was an investor director with the London-based venture capital firm Merlin Biosciences Limited and, from 1987 to 2000, was chief executive officer of the technology transfer company Cancer Research Campaign Technology Limited. She studied biochemistry at the University of Oxford, obtaining an MA and a DPhil.
Dr Marc d’Abbadie, Non-Executive Director
Marc is an investor director at SPARK Impact, managers of the North West Fund for Biomedical. He was previously at Inventages, which manages one of the world’s largest life-science focused venture capital funds with assets of $1.5bn, and Technikos, a medical device venture capital investor. Prior to being a consultant at McKinsey & Co., Marc was a research fellow at Trinity College Cambridge. He obtained his MA in Natural Sciences from Trinity College Cambridge and his PhD in Biochemistry from the MRC Laboratory of Molecular Biology, also at Cambridge.
David Chadwick, Head of Clinical Operations
Dave has over 25 years’ experience in the healthcare and clinical research industry. His previous roles include: Senior Clinical Manager for Quintiles, Senior Project Manager and Independent Clinical Auditor for ICON Development Solutions Plc, Associate Director of Clinical Operations at Illingworth Research Limited and Operations and Project Director at Acumen Pharmaceuticals. Prior to entering the clinical research industry, he was a Paramedic and Paramedic Training Officer for the Mersey Regional Ambulance Service.
Dr Robert Holland – Medical Advisor (Neurology)
Bob is a physician with a DPhil in neuroscience. After medical practice in Oxford and in London, he joined the pharmaceutical industry in 1985 gaining substantial experience across multiple therapeutic areas, working for a number of major companies across all phases of drug discovery and development, living and working in The Netherlands, Belgium, Sweden and The UK. Between 1999 and 2005, Bob was responsible for all Phase 1 and early Phase 2 studies for all AstraZeneca drugs across all indications. From 2005 until 2010, Bob led the Neuroscience Therapeutic Area for AstraZeneca (Discovery and Development) after which he created the novel “Personalised Healthcare & Biomarkers” function for that company.
Dr Thomas Morris – Medical Advisor (Oncology)
Tom is a physician who has worked in pharmaceutical medicine and drug development for over 20 years with much of this time specialising in oncology. After several years working in clinical medicine, he joined firstly Medeval Ltd (University of Manchester) and then AstraZeneca, where he has held a number of global R&D roles. Most recently these included Senior Medical Director and Executive Director Clinical Programs. He has overseen several global drug development programs, interacting with leading external medical and scientific experts, academic groups and regulatory agencies worldwide and brings a wealth of experience in drug development.
Liz Jenkins – Regulatory Consultant
Liz Jenkins is a specialist in International Regulatory Affairs with over 30 years’ experience in the biopharmaceutical sector. She started her career at the East Birmingham and Royal Free Hospitals before joining Celltech Ltd (now UCB Celltech) in 1983 and the Amgen in 1993. Since 1998 Liz has operated as both an independent or affiliated consultant offering strategic advice and practical assistance in the areas of drug development, clinical trials, regulatory affairs and product licensing to more than 50 different biopharmaceutical companies.